Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity‐score matched cohort study

2021 ◽  
Author(s):  
Weihang Zhou ◽  
Yiwei Jiang ◽  
Yaqian Xu ◽  
Yaohui Wang ◽  
Xiaowei Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Propensity Score ◽  
Cancer Patients ◽  
Adverse Drug Reactions ◽  
Matched Cohort ◽  
Breast Cancer Patients ◽  
Drug Reactions ◽  
Matched Cohort Study

scholarly journals Effect of multidisciplinary team care on the risk of recurrence in breast cancer patients: A national matched cohort study

The Breast ◽  
2020 ◽  
Vol 53 ◽  
pp. 68-76 ◽  
Author(s):  
Chang-Hung Tsai ◽  
Huan-Fa Hsieh ◽  
Ting-Wei Lai ◽  
Pei-Tseng Kung ◽  
Wei-Yin Kuo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Multidisciplinary Team ◽  
Matched Cohort ◽  
Breast Cancer Patients ◽  
Risk Of Recurrence ◽  
Matched Cohort Study ◽  
Team Care

scholarly journals Safety of fertility preservation in breast cancer patients in a register-based matched cohort study

2017 ◽  
Vol 167 (3) ◽  
pp. 761-769 ◽  
Author(s):  
Kenny A. Rodriguez-Wallberg ◽  
Sandra Eloranta ◽  
Kamilla Krawiec ◽  
Agneta Lissmats ◽  
Jonas Bergh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Matched Cohort ◽  
Breast Cancer Patients ◽  
Matched Cohort Study

scholarly journals Long-term oncologic safety of immediate reconstructive surgery in patients with invasive breast cancer: a retrospective matched-cohort study

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yanni Song ◽  
Shanshan Sun ◽  
Dalin Li ◽  
Jiguang Han ◽  
Ming Niu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Patient Satisfaction ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Well Being ◽  
Secondary Outcome ◽  
Matched Cohort ◽  
Breast Cancer Patients ◽  
Matched Cohort Study

Abstract Objective Immediate reconstruction (IR) is a safe and effective surgical treatment for patients with breast cancer. We aimed to assess the prognosis, aesthetic outcomes, and patient satisfaction of IR compared with breast conservation surgery (BCS) and total mastectomy (TM). Methods This retrospective matched-cohort study was conducted between May 2005 and December 2014. We established two cohorts according to the tumor (T) size of breast cancer. In the T≤3cm group, cases (IR) and controls (BCS or TM) were matched for age, pathological tumor size, and pathologic nodal status in a 1:1:1 ratio. In the T>3cm group, cases (IR) and controls (TM) were matched with the same factors and ratio. The primary outcome was the 5-year disease-free survival (DFS). The secondary outcome was patient satisfaction and quality of life. Results A total of 12,678 breast cancer patients were assessed for eligibility, of which 587 were included (T≤3 cm group: 155 IR vs 155 BCS vs 155 TM; T>3cm group: 61 IR vs 61 TM). In the T≤3 cm cohort, patients who underwent IR had no difference compared with those who underwent BCS or TM regarding the 5-year DFS (P=0.539); however, an improved aesthetic satisfaction, psychosocial, and sexual well-being were achieved in the IR group (P<0.001). In the T>3 cm cohort, the IR group had a worse median 5-year DFS (P=0.044), especially for Her2+ or triple-negative breast carcinoma (TNBC) subtypes compared with the TM group. Conclusions IR improves aesthetic satisfaction, psychosocial, and sexual well-being for breast cancer patients with T≤3 cm. For patients with T > 3 cm invasive breast cancer, TM is superior to IR as it predicts a better 5-year DFS.

scholarly journals Long-Term Oncologic Safety of Immediate Reconstructive Surgery in Patients with Invasive Breast Cancer: A Retrospective Matched-Cohort Study

2021 ◽  
Author(s):  
Yanni Song ◽  
Shanshan Sun ◽  
Dalin Li ◽  
Jiguang Han ◽  
Ming Niu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Patient Satisfaction ◽  
Cancer Patients ◽  
Breast Conservation ◽  
Well Being ◽  
Secondary Outcome ◽  
Matched Cohort ◽  
Breast Cancer Patients ◽  
Matched Cohort Study

Abstract Objective Immediate reconstruction (IR) is a safe and effective surgical treatment for patients with breast cancer. We aimed to assess the prognosis, aesthetic outcomes, and patient satisfaction of IR compared with breast conservation surgery (BCS) and total mastectomy (TM).Methods In this retrospective matched-cohort study, we established two cohorts according to the tumor (T) size of breast cancer. In the T≤3cm group, cases (IR) and controls (BCS or TM) were matched for age, pathological tumor size and pathologic nodal status in a 1:1:1 ratio. In the T>3cm group, cases (IR) and controls (TM) were matched with the same factors and ratio. The primary outcome was the 5-year disease-free survival (DFS). The secondary outcome was patient satisfaction and quality of life.Results Between May, 2005 and December, 2014, total 12,678 breast cancer patients were assessed, of which 587 were included (T≤3 cm group: 155 IR vs 155 BCS vs 155 TM; T>3cm group: 61 IR vs 61 TM). In the T≤3 cm cohort, patients underwent IR had no difference compared with those underwent BCS or TM regarding the 5-year DFS (P=0.539); however, an improved aesthetic satisfaction, psychosocial and sexual well-being were achieved in the IR group (P＜0.001). In the T>3 cm cohort, IR group had a worse median 5-year DFS (P=0.044), especially for Her2+ or triple-negative breast carcinoma (TNBC) subtypes compared with TM group. Conclusions IR improves aesthetic satisfaction, psychosocial and sexual well-being for breast cancer patients with T≤3 cm. However, Her2+ or TNBC predict a worse 5-year DFS in the T>3 cm group.

scholarly journals Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan

2021 ◽  
Vol 11 ◽  
Author(s):  
Yin-Che Lu ◽  
Pin-Tzu Chen ◽  
Mei-Chen Lin ◽  
Che-Chen Lin ◽  
Shi-Heng Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Propensity Score ◽  
Cancer Risk ◽  
Population Based ◽  
Matched Cohort ◽  
Second Cancer ◽  
Matched Cohort Study ◽  
Inflammatory Drugs ◽  
Second Cancer Risk

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce mortality in patients with cancer, especially breast cancer, but their influence on second cancer risk is uncertain. This study aimed to examine whether NSAID use is associated with second cancer risk in patients with breast cancer. This population-based propensity score-matched cohort study using Taiwan’s National Health Insurance Research Database enrolled patients with newly diagnosed breast cancer (n = 7356) with and without (n = 1839) NSAID therapy from 2000 to 2009. They were followed up until the diagnosis of second cancer, death, or end of 2011. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR). The NSAID cohort had a lower incidence rate of second cancer than the non-NSAID cohort (5.57 vs. 9.19 per 1,000 person-years), with an aHR of 0.63 (95% confidence interval (CI) 0.46–0.87). When compared with the non-NSAID cohort, the second cancer incidence was lower in patients taking non-cyclooxygenase 2 inhibitors (aHR 0.67, 95% CI 0.47–0.94) and in those receiving multiple NSAIDs during follow-up (aHR 0.55, 95% CI 0.37–0.84). A dose–response relationship existed in NSAID cumulative days. The findings demonstrate that NSAID use reduces second cancer risk in a dose-dependent manner in patients with primary breast cancer.

scholarly journals Drug Utilisation Pattern and Adverse Drug Reactions in Stage II Breast Cancer Patients in a Tertiary Care Centre of Odisha- An Observational Study

2021 ◽  
Author(s):  
Anima Rout ◽  
Priti Das ◽  
Ratikanta Tripathy ◽  
Dillip Kumar Agarwalla ◽  
Vedvyas Mishra
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Cancer Patients ◽  
Adverse Drug Reactions ◽  
Tertiary Care ◽  
Stage Ii ◽  
World Health ◽  
Combination Regimen ◽  
Breast Cancer Patients ◽  
Drug Reactions

Introduction: Breast cancer is the most common cancer occurring in women with an estimated prevalence of 28.94% in Cuttack, Odisha, India. Adverse Drug Reactions (ADRs) associated with the use of anticancer drugs is a worldwide problem which needs further attention. Aim: To know about treatment regimens, premedications used for toxicity amelioration or any associated ADRs occurring during treatment of stage II breast cancer patients. Materials and Methods: This was a prospective observational study carried out in the Department of Pharmacology in collabo- ration with Acharya Harihar Regional Cancer Center (AHRCC), SCB Medical College and Hospital, Odisha, India. A total of 181 female breast cancer patients of stage II were finally analysed about their treatment protocol pattern including premedication, chemotherapy regimen, associated ADRs and their treatment. Different outcomes measured were Absolute Neutrophil Count (ANC), febrile neutropenia, anaemia, thrombocytopenia. ADRs were analysed by using World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) Scale and Hartwig-Siegel Scale. All analysis was performed using Statistical Package For the Social Sciences (SPSS) version 18.0. Results: Most common chemotherapy combination regimen used was cyclophosphamide+doxorubicin+paclitaxel+trastuzumab in 30.9% of patients, out of which 28.7% showed ADRs. Ondansetron and aprepitant were commonly used as premedication in 96% of patients. Most commonly reported ADR was Chemotherapy Induced Nausea and Vomiting (CINV) in 43.6% patients and Chemotherapy Induced Neutropenia (CIN) (34.8%). Fifty percent ADRs were mild and 3.3% ADRs were severe in nature. A 64% ADRs were possible and 23% ADRs were probable according to WHO-UMC causality assessment scale. Grade 4 Neutropenia was present in 1.3% patients. Mild haematological problems were treated by blood transfusion while severe cases by additional growth factor support like Granulocyte Colony Stimulating Factor (G-CSF). In this study, mean age of presentation was found to be 44.6 years. Conclusion: Despite use of drugs for toxicity amelioration, some grade four life threatening ADRs were observed. Mostly ADRs were missed and under-reported. Regular monitoring, increased care and patient compliance was needed to detect new ADRs and to reduce the morbidity as well as burden on the patients.

Sign in / Sign up

Export Citation Format

Share Document